Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia
NCT ID: NCT07094022
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2025-03-16
2025-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Does the intake of the study product improve the blood lipid profiles (TC,TG, LDL-C ) in terms of of overweight individuals with dyslipidemia?
Researchers will compare the product group to a placebo group to see whether the blood lipid profile is significantly better improved for participants in the product group.
Participants will:
* take randomly assigned products 16g/each time, twice a day for 4 weeks
* make four times site visits, once a week. Blood samples are collected for each visit, and Feces are collected for the first and last site visit.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Soy Protein Intake and the Metabolic Syndrome
NCT01694056
Protein Supplementation Intervention on Body Weight
NCT06989203
Effects of a Marine Protein Hydrolysate in Healthy Adults
NCT05149079
Calcium-protein Co-ingestion and Gut Hormones
NCT03370497
Metabolic and Appetite Responses to a Whey Protein Preload Following Prior Exercise in Overweight Males
NCT02714309
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nutrilite Protein MetX Pro
Nutrilite protein MetX pro, 460g per pack. Ingredients: Mung bean protein, chickpea protein, isomaltulose, rice (glutinous rice) protein, green apple concentrated juice powder, inulin, xanthan gum, guar gum, silicon dioxide, food flavoring.
Nutrilite Protein MetX Pro
A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
Placebo Product
Placebo product , 460g per pack. Ingredient: Maltodextrin.
Placebo Product
A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutrilite Protein MetX Pro
A total of 4 cans (460 g/can) of study products (Nutrilite Protein MetX Pro) are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
Placebo Product
A total of 4 cans (460 g/can) of placebo products are distributed to each participant. Participants need to take 16g each time, twice a day, for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Overweight or obese participants, 40 with a BMI of 24-28 kg/m², and 40 participants with a BMI greater than 28. The percentage of male participants is ≥40%. And the lipid profile with the following characteristics:
* TC (Total Cholesterol): 5.18-6.21 mmol/L;
* TG(Triglyceride): 1.70-2.25 mmol/L;
* LDL-C(Low-Density Lipoprotein Cholesterol): ≥ 3.4 mmol/L;
* Agree to sign the informed consent form.
Exclusion Criteria
* Patients with severe diseases of the heart, liver, kidneys and hematopoietic system, as well as those with mental illness.
* Those who have taken lipid-lowering drugs or the like in the past two weeks, which has affected their judgment of the results.
* Patients with hyperlipidemia.
* The researcher determined that the participant was not suitable for this trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amway (China) R&D Center
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dan Cao
Role: PRINCIPAL_INVESTIGATOR
Jinhua Wenrong Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Raison Biotech Group Shanghai Lab
Shanghai, Shanghai Municipality, China
Jinhua Wenrong Hospital
Jinhua, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-RD-08-AY-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.